Talazoparib Add-On Improves Outcomes in Metastatic Prostate Cancer

For patients with metastatic castration-resistant prostate cancer, talazoparib combined with enzalutamide achieved better progression-free survival than enzalutamide alone.

Related Keywords

Pennsylvania ,United States ,Canada ,Fox Chase Cancer Center ,Spain ,Philadelphia ,America ,Astellas Pharma ,Neeraj Agarwal ,Selena Castro ,Matthew Zibelman ,Bristol Myers Squibb ,Roche Zibelman ,Huntsman Cancer Institute ,University Of Utah ,Novartis ,Genitourinary Oncology Program ,Pfizer ,Astrazeneca ,Serono ,Department Of Hematology Oncology ,Genitourinary Cancers Symposium ,Instituto De Investigaci ,South America ,Adverse Events ,Clovis Oncology ,Cancers Symposium ,Prostate Carcinoma ,Alignant Prostate Neoplasm ,Prostate Cancer ,Ancer Prostate ,Breast Cancer ,Alignant Breast Neoplasm ,Cancer ,Alignant Neoplasia ,Arcinoma ,Prostatic ,Biologic Therapy ,Genomics ,Genomic Medicine ,Edicine Genomic ,Prostate Specific Antigen Psa ,Prostate Specific Antigen ,Sa ,Tumor ,Parp Inhibitors ,Parp Inhibition ,Oly Adp Ribose Polymerase Inhibitor ,Myelodysplastic Syndr ,